Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Share-based Compensation (2020 - 2026)

Immuneering's Share-based Compensation history spans 7 years, with the latest figure at $1.6 million for Q1 2026.

  • On a quarterly basis, Share-based Compensation fell 3.29% to $1.6 million in Q1 2026 year-over-year; TTM through Mar 2026 was $6.3 million, a 6.9% decrease, with the full-year FY2025 number at $6.3 million, down 2.93% from a year prior.
  • Share-based Compensation came in at $1.6 million for Q1 2026, roughly flat from $1.6 million in the prior quarter.
  • The five-year high for Share-based Compensation was $1.7 million in Q4 2024, with the low at $897650.0 in Q1 2022.
  • Historically, Share-based Compensation has averaged $1.4 million across 5 years, with a median of $1.5 million in 2023.
  • Biggest five-year swings in Share-based Compensation: surged 392.61% in 2022 and later fell 11.22% in 2025.
  • Year by year, Share-based Compensation stood at $1.0 million in 2022, then surged by 56.52% to $1.6 million in 2023, then increased by 5.13% to $1.7 million in 2024, then fell by 5.04% to $1.6 million in 2025, then decreased by 0.07% to $1.6 million in 2026.
  • Business Quant data shows Share-based Compensation for IMRX at $1.6 million in Q1 2026, $1.6 million in Q4 2025, and $1.5 million in Q3 2025.